NCT06810609

Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

Prospective Randomized Phase II Trial on Induction Immunochemotherapy Followed by Surgery or Definitive Chemoradiation and Consolidation Durvalumab (MEDI4736) in Resectable and Borderline Resectable Stage IIIA/B NSCLC

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 176 (estimated)
• Sponsor: University Hospital, Bonn · Academic / Other
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

The hypothesis of the study is that induction immunochemotherapy, followed by surgery or chemoradiation and consolidation Durvalumab immunotherapy, can significantly improve event-free survival in patients with resectable or borderline resectable NSCLC at stage IIIA/B compared to existing treatment methods.

Conditions

• Lung Cancer Non-Small Cell Cancer (NSCLC)

Interventions

Type	Name	Description
PROCEDURE	surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines	Surgical removal of the tumor in patients with resectable or borderline resectable NSCLC
RADIATION	Chemoradiotherapy	Chemoradiotherapy
DRUG	Immunotherapy	Immunotherapy (Durvalumab).

Timeline

• Start date: 2025-04-20
• Primary completion: 2029-12-31
• Completion: 2030-09-30
• First posted: 2025-02-05
• Last updated: 2026-01-27

Locations

5 sites across 1 country: Germany